VYNE Therapeutics (NASDAQ:VYNE) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.22) by 41.7 percent. This is a 40.91 percent increase over losses of $(0.22) per share from the same period last year. The company reported quarterly sales of $69.000 thousand which missed the analyst consensus estimate of $150.000 thousand by 54.00 percent. This is a 65.15 percent decrease over sales of $198.000 thousand the same period last year.